New RSV vaccine trial aims to protect adults from severe lung infections
⭐️ VACCINE ⭐️
Not yet recruiting
This study tests a new vaccine against respiratory syncytial virus (RSV) in adults. It involves 470 participants aged 18 and older (phase I) and 60 and older (phase II). The goal is to see if the vaccine is safe and triggers a strong immune response.
Phase: PHASE1, PHASE2 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 10:24 UTC